Home > Boards > US Listed > Biotechs > Can-Fite BioPharma (CANF)

CANF Can-Fite ADRs Up; To Advance Piclidenoson into

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
swanlinbar Member Profile
 
Followed By 71
Posts 11,381
Boards Moderated 9
Alias Born 08/09/00
160x600 placeholder
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 7/6/2020 8:09:50 AM
Can-Fite Announces $3.4 Million Registered Direct Offering Business Wire - 7/6/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/30/2020 7:08:57 AM
Can-Fite Announces Final Data Analysis from Phase II NASH Study: Business Wire - 6/30/2020 7:00:00 AM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 6/19/2020 4:36:29 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 4:24:38 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 6/19/2020 6:03:47 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/12/2020 8:30:54 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/12/2020 8:04:03 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/10/2020 8:11:22 AM
Can-Fite Announces $8.0 Million Registered Direct Offering Business Wire - 6/10/2020 8:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/9/2020 7:05:20 AM
Following Pre-IND Guidance from FDA Can-Fite to Advance Piclidenoson into Phase II COVID-19 Trial in the U.S. Business Wire - 6/9/2020 7:00:00 AM
Can-Fite Participating in BIO Digital International Convention and One-on-One Partnering Meetings on June 8-12, 2020 Business Wire - 6/8/2020 7:25:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/4/2020 7:22:28 AM
Can-Fite Concludes Successful Meeting with European Medicines Agency (EMA) Regarding Phase III Trial & Registration Plan for ... Business Wire - 6/4/2020 7:14:00 AM
Can-Fite BioPharma to Hold Investor Webinar and Q&A Session with CEO on June 4th Business Wire - 6/3/2020 7:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 6/1/2020 7:24:12 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 6/1/2020 7:07:32 AM
Can-Fite Reports First Quarter 2020 Financial Results & Provides Clinical Update Business Wire - 6/1/2020 7:00:00 AM
Can-Fite to Host First Quarter 2020 Financial Results & Clinical Update Conference Call on June 1, 2020 Business Wire - 5/28/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/21/2020 7:13:58 AM
Can-Fite Receives Notice of Allowance for Namodenoson Patent in the Treatment of NASH & NAFLD from U.S. Patent & Trademark Of... Business Wire - 5/21/2020 7:00:00 AM
Report of Foreign Issuer (6-k) Edgar (US Regulatory) - 5/18/2020 7:09:21 AM
Can-Fite Reports Additional Findings from Successful Phase II NASH Study: 25 mg Dose of Namodenoson Significantly Reduced Liv... Business Wire - 5/18/2020 7:00:00 AM
swanlinbar   Tuesday, 06/09/20 03:19:36 PM
Re: None
Post # of 1454 
CANF Can-Fite ADRs Up; To Advance Piclidenoson into Phase II Covid-19 Trial in U.S.
7:53 am ET June 9, 2020 (Dow Jones) Print
By Michael Dabaie

Can-Fite BioPharma Ltd. ADRs were up 16%, to $2.37, premarket.

The biotechnology company said that in response to Can-Fite's Pre-Investigational New Drug filing with the U.S. Food and Drug Administration, the FDA has provided detailed comments regarding the prospective use of Piclidenoson to treat patients suffering from Covid-19.

The FDA's response allows Can-Fite to proceed to the next step of formally submitting an IND for Piclidenoson in this indication.

The planned Phase II trial will evaluate the efficacy and safety of Piclidenoson, when added to the current standard of care treatment, for Covid-19 infected patients with moderate-to-severe symptoms.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

June 09, 2020 07:53 ET (11:53 GMT)

"that a rich man is not the one who has the most but the one who needs the least"
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist